1. Hollmann P, and Lundebjerg NE, (2021, June 2). Food and drug administration's review of Biogen's drug aducanumab for Alzheimer's disease. https://www.americangeriatrics.org/sites/default/files/inline-files/American%20Geriatrics%20Society_ Letter%20to%20FDA%20Biogen%20Drug%20for%20Alzheimer%27s%20%28June% 202021%29%20FINAL%20%281%29.pdf. Accessed December 9, 2021.
2. American Geriatrics Society, Society for post-acute and long-term care medicine, society of general internal medicine, & society of nuclear medicine & molecular imaging. (2021, September 30). AGS, AMDA, SGIM, SNMMI Joint Letter to FDA on Aducanumab Label. https://www.americangeriatrics.org/sites/default/files/inline-files/Joint%20Letter%20to%20FDA%20on%20Aducanumab%20Label%20%289% 2030% 2021 %29_FINAL.pdf. Accessed December 9, 2021.
3. Hollmann P, and Lundebjerg NE, (2021, August 11). Comments on national coverage analysis for aducanumab for treatment of Alzheimer's disease. https://www.americangeriatrics.org/sites/default/files/inline-files/American%20Geriatrics%20Society%20Aducanumab%20NCD%20Comments%208%2011%2021_Final.pdf. Accessed December 9, 2021.
4. American Academy of Neurology, American geriatrics society, & society of nuclear medicine & molecular imaging. (2021, July 19). Joint AGS, AAN, SNMMI Letter to CMS on Beta Amyloid PET Coverage. https://www.americangeriatrics.org/sites/default/files/inline-files/CMS%20Letter%20on%20Beta%20Amyloid%20PET%20coverage% 20071921%20-%20FINAL_0.pdf. Accessed December 9, 2021.
5. American Academy of Neurology, American geriatrics society, & society of nuclearmedicine and molecular imaging. (2021, November 22). AAN, AGS, SNMMI joint letter to CMS on Medicare Coverage for Aducanumab. https://www.americangeriatrics.org/sites/default/files/inline-files/Joint%20Letter%20to%20CMS%20on%20 Medicare%20 Coverage%20for%20Aducanumab.pdf. Accessed December 10, 2021.